EP-547 is under clinical development by Escient Pharmaceuticals and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs for Pruritus have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EP-547’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EP-547 overview

EP-547 is under developmant for the treatment of cholestatic pruritus due to primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC), uremic pruritis, hepatitis B and hepatitis C. It is administered through oral route. It acts by targeting MRGPRX4 (Mas-related G Protein-Coupled Receptor-X4).

Escient Pharmaceuticals overview

Escient Pharmaceuticals is a pharmaceutical and healthcare company. It develops and commercialize drugs targeting G protein-coupled receptor (GPCRs) for unmet medical needs. The company aims to develop therapies for neuro-immuno-inflammatory and autoreactive diseases. In addition, it’s MrgprX4 and MrgprX2 for treatment of cholestatic and uremic pruritus. It is funded by Osage University Partners, The Column Group and 5AM Ventures, Sanofi Ventures, Cowen, Perceptive Advisors, Redmile Group and Altitude Life Science Ventures. Escient Pharmaceuticals is headquartered in San Diego, California, the US.

For a complete picture of EP-547’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.